# US 2021/0340564 A1 · Efficient selectivity of recombinant proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340564 A1
- Document ID: US20210340564A1
- Status: Published application
- Kind: A1
- Application number: 17/366,239
- Filed: 2021-07-02
- Published: 2021-11-04
- Earliest claimed: 2014-08-19
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Dipali Deshpande; Darya Burakov; Gang Chen; James Fandl
- Web page: https://patentgrep.com/patent/US20210340564A1

## CPC

- C12N 15/85: for animal cells
- C12P 21/005: {Glycopeptides, glycoproteins}
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.

## Claims

### Claim at position 1

-29. (canceled)

### Claim 30

A method of employing tunicamycin (Tn) as a selection marker in mammalian cell culture, comprising
(a) providing a mammalian host cell population,
(b) introducing into the cell population of step (a) a nucleic acid by transfection to permit integration of the nucleic acid into a target locus, wherein the nucleic acid comprises (i) a mammalian tunicamycin (Tn)-resistance gene encoding a protein having at least 93% identity to the amino acid sequence of SEQ ID NO: 3, and (ii) a first a gene of interest (GOI),
(c) culturing the cell population of step (b) in the presence of Tn, and
(d) obtaining a cell transfectant that comprises said nucleic acid integrated in the target locus.

### Claim 31 (depends on 30)

The method of claim 30, wherein said integration into the target locus is mediated by a recombinase that recognizes a specific site in the target locus.

### Claim 32 (depends on 30)

The method of claim 30, wherein said integration into the target locus is mediated by homologous recombination.

### Claim 33 (depends on 30)

The method of claim 30, wherein said homologous recombination is facilitated by a nuclease that cleaves a sequence within the target locus.

### Claim 34 (depends on 33)

The method of claim 33, wherein said nuclease is selected from a zinc finger nuclease (ZFN), a transcription activator-like effector nuclease (TALEN), or an RNA-guided endonuclease.

### Claim 35 (depends on 30)

The method of claim 30, wherein said culturing in step (c) comprises culturing in sequentially increasing concentrations of Tn.

### Claim 36 (depends on 30)

The method of claim 30, wherein said culturing in step (c) comprises culturing in the presence of Tn at a first concentration, and wherein the cell transfectant obtained from step (d) is further cultured in the presence of Tn at a second concentration higher than the first concentration.

### Claim 37 (depends on 30)

The method of claim 30, wherein the Tn-resistance gene encodes a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.

### Claim 38 (depends on 37)

The method of claim 37, wherein the Tn-resistance gene comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17.

### Claim 39 (depends on 30)

The method of claim 30, wherein the first GOI encodes a first protein of interest (POI).

### Claim 40 (depends on 39)

The method of claim 39, further comprising expressing said first POI from said first GOI and isolating said first POI from the cultured cell transfectant.

### Claim 41 (depends on 30)

The method of claim 30, wherein the mammalian host cell is selected from the group consisting of CHO, COS-7, HEK293, tumor cell, lymphocyte, retinal cell, and stem cell.

### Claim 42 (depends on 30)

The method of claim 30, wherein the mammalian host cell is a CHO cell.
